These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7596589)

  • 1. [Role and behavior of cathepsin B and cathepsin L in gastric cancer].
    Herszényi L; Plebani M; Carraro P; De Paoli M; Roveroni G; Rugge M; Cardin R; Naccarato R; Farinati F
    Orv Hetil; 1995 Jun; 136(25):1315-8. PubMed ID: 7596589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cysteine and serine proteases in gastric cancer.
    Plebani M; Herszènyi L; Cardin R; Roveroni G; Carraro P; Paoli MD; Rugge M; Grigioni WF; Nitti D; Naccarato R
    Cancer; 1995 Aug; 76(3):367-75. PubMed ID: 8625115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of cysteine and serine proteases in colorectal carcinoma.
    Herszènyi L; Plebani M; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
    Cancer; 1999 Oct; 86(7):1135-42. PubMed ID: 10506696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cathepsin B and L activities in gastric cancer tissue: correlation with histological findings.
    Watanabe M; Higashi T; Watanabe A; Osawa T; Sato Y; Kimura Y; Tominaga S; Hashimoto N; Yoshida Y; Morimoto S
    Biochem Med Metab Biol; 1989 Aug; 42(1):21-9. PubMed ID: 2775560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis.
    Farinati F; Herszényi L; Plebani M; Carraro P; De Paoli M; Cardin R; Roveroni G; Rugge M; Nitti D; Grigioni WF; D'Errico A; Naccarato R
    Carcinogenesis; 1996 Dec; 17(12):2581-7. PubMed ID: 9006092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunostained cathepsins B and L correlate with depth of invasion and different metastatic pathways in early stage gastric carcinoma.
    Dohchin A; Suzuki JI; Seki H; Masutani M; Shiroto H; Kawakami Y
    Cancer; 2000 Aug; 89(3):482-7. PubMed ID: 10931446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer].
    Herszényi L; Farinati F; Plebani M; István G; Sápi Z; Carraro P; De Paoli M; Naccarato R; Tulassay Z
    Orv Hetil; 1999 Aug; 140(33):1833-6. PubMed ID: 10489782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators.
    Lah TT; Cercek M; Blejec A; Kos J; Gorodetsky E; Somers R; Daskal I
    Clin Cancer Res; 2000 Feb; 6(2):578-84. PubMed ID: 10690542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer.
    Thomssen C; Schmitt M; Goretzki L; Oppelt P; Pache L; Dettmar P; Jänicke F; Graeff H
    Clin Cancer Res; 1995 Jul; 1(7):741-6. PubMed ID: 9816040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of cathepsins B and L in primary human breast cancer.
    Foekens JA; Kos J; Peters HA; Krasovec M; Look MP; Cimerman N; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    J Clin Oncol; 1998 Mar; 16(3):1013-21. PubMed ID: 9508185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevation of tissue cathepsin B and L activities in gastric cancer.
    Watanabe M; Higashi T; Hashimoto M; Tomoda I; Tominaga S; Hashimoto N; Morimoto S; Yamauchi Y; Nakatsukasa H; Kobayashi M
    Hepatogastroenterology; 1987 Jun; 34(3):120-2. PubMed ID: 3610018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of cathepsin B and L expression in vitro in gastric cancer tissues by egg cystatin.
    Saleh Y; Siewiński M; Kielan W; Ziółkowski P; Gryboś M; Rybka J
    J Exp Ther Oncol; 2003; 3(6):319-24. PubMed ID: 14678520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of cysteine proteinases cathepsins B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck.
    Strojan P; Budihna M; Smid L; Svetic B; Vrhovec I; Kos J; Skrk J
    Clin Cancer Res; 2000 Mar; 6(3):1052-62. PubMed ID: 10741734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrigel invasion by the prostate cancer cell lines, PC3 and DU145, and cathepsin L+B activity.
    Colella R; Jackson T; Goodwyn E
    Biotech Histochem; 2004; 79(3-4):121-7. PubMed ID: 15621884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variable expression of cathepsin B and D correlates with highly invasive and metastatic phenotype of oral cancer.
    Vigneswaran N; Zhao W; Dassanayake A; Muller S; Miller DM; Zacharias W
    Hum Pathol; 2000 Aug; 31(8):931-7. PubMed ID: 10987253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Protease activities in gastric and colon cancer tissues].
    Chung SM; Kawai K; Chung HM; Kawamoto K; Tada M
    Nihon Shokakibyo Gakkai Zasshi; 1990 Aug; 87(8):1678-85. PubMed ID: 2232301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis.
    Lah TT; Kalman E; Najjar D; Gorodetsky E; Brennan P; Somers R; Daskal I
    Hum Pathol; 2000 Feb; 31(2):149-60. PubMed ID: 10685628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic role of cisteine and serin proteases in gastriC cancer].
    Herszényi L; Farinati F; Plebani M; Carraro P; Roveroni G; De Paoli M; Cardin R; Naccarato R; Tulassay Z
    Orv Hetil; 1996 Jul; 137(30):1637-41. PubMed ID: 9019701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progression.
    Troy AM; Sheahan K; Mulcahy HE; Duffy MJ; Hyland JM; O'Donoghue DP
    Eur J Cancer; 2004 Jul; 40(10):1610-6. PubMed ID: 15196548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.
    Thomssen C; Oppelt P; Jänicke F; Ulm K; Harbeck N; Höfler H; Kuhn W; Graeff H; Schmitt M
    Anticancer Res; 1998; 18(3C):2173-80. PubMed ID: 9703780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.